Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 13Sarcoma 4Gynecologic 3Genitourinary 3Thoracic 2CNS 2Tumor-Agnostic 1Head & Neck 1Dermatologic 1

Conditions

Oropharyngeal Neoplasms 1

Interventions

Cisplatin 85pembrolizumab 76Magnetic Resonance Spectroscopy 46Radiotherapy, Intensity-Modulated 41Specimen Handling 36Cetuximab 36Carboplatin 35Radiotherapy 34Nivolumab 28Paclitaxel 24Radiation 22Platinum 22Docetaxel 20Biopsy 201,2-diaminocyclohexaneplatinum II citrate 20Gemcitabine 19Surveys and Questionnaires 15Fluorouracil 14toripalimab 13Standard of Care 12Taxes 11cemiplimab 9atezolizumab 9Ipilimumab 9Drug Therapy 9Cyclophosphamide 9X-Rays 8Surgical Procedures, Operative 8Radiosurgery 7Immunoglobulin G 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
balstilimab × Head & Neck × 90 days × Clear all
NCT05363709 2026-05-12

BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Head & Neck

Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡